Reuters logo
BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting
September 5, 2017 / 11:16 AM / in 3 months

BRIEF-Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting

Sept 5 (Reuters) - Citius Pharmaceuticals Inc:

* Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting

* Citius Pharmaceuticals, Inc. Provides phase 3 update on mino-lok™ clinical trial following FDA meeting

* Citius Pharmaceuticals Inc - ‍citius is currently recruiting sites for a phase 3 trial of Mino-Lok in United States​

* Citius Pharmaceuticals Inc - ‍received feedback from u. s. Food and drug administration regarding amendments to phase 3 study plan for Mino-Lok​

* Citius pharmaceuticals inc - ‍following discussion with FDA, Citius amended phase 3 study design to remove saline and heparin placebo control arm​

* Citius Pharmaceuticals Inc - ‍fda agreed that an open label, superiority design would address company’s concerns and would be acceptable for Mino-Lok​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below